Philip Astley-Sparke
Chief Executive Officer at Replimune Group Inc.
Sits on 2 boards. Last updated September 28, 2026
Time on boards
- Boards served
- 2
- Current seats
- 2
- Board service
- 5 years
- Director since
- 2023
5 years of board service in total across 2 boards, counting each seat separately. Longest: Replimune Group Inc., 3 years.
Chief executive roles
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
enGene Therapeutics Inc. June 9, 202699.4%
-
Replimune Group Inc. September 2, 202595.9%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 20, 2026 | Replimune Group Inc. | Gift | −50,000 | — | — |
| May 18, 2026 | Replimune Group Inc. | Open-market sale | −17,657 | $5.08 | $89,698 |
| Apr 1, 2026 | Replimune Group Inc. | Grant or award | +50,000 | — | — |
| Feb 18, 2026 | Replimune Group Inc. | Gift | −25,000 | — | — |
| May 20, 2025 | Replimune Group Inc. | Open-market sale | −32,279 | $8.06 | $260,169 |
| Aug 30, 2024 | Replimune Group Inc. | Gift | −50,000 | — | — |
| May 16, 2024 | Replimune Group Inc. | Open-market sale | −37,928 | $6.47 | $245,394 |
| May 16, 2023 | Replimune Group Inc. | Open-market sale | −17,902 | $18.05 | $323,131 |
| Apr 1, 2023 | Replimune Group Inc. | Grant or award | +142,100 | — | — |
Questions about Philip Astley-Sparke
What boards is Philip Astley-Sparke on?
Philip Astley-Sparke sits on the boards of Replimune Group Inc. and enGene Therapeutics Inc.
What company is Philip Astley-Sparke the CEO of?
Philip Astley-Sparke is Chief Executive Officer of Replimune Group Inc.
How long has Philip Astley-Sparke served on boards?
Our records show at least 5 years of board service across 2 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.